IGF1-LR3 – Pharmaqo Labs

IGF-1 LR3 Pharmaqo for sale in the UK

IGF-1 LR3 (Long R3) by Pharmaqo Labs is a long-acting synthetic IGF-1 analogue used by experienced bodybuilders and recovery-focused athletes to drive systemic anabolic signalling — particularly hyperplasia, the growth of new muscle cells via the IGF-1 receptor. If you want to buy IGF-1 LR3 UK from a verified source, each vial sold here is lab-tested and shipped same working day from our UK warehouse.

What is IGF-1 LR3?

IGF-1 LR3 is a modified version of human insulin-like growth factor 1, engineered with an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus. These changes dramatically reduce its affinity for the IGF binding proteins (IGFBPs) that ordinarily clear native IGF-1 from circulation within minutes. The practical result is an extended active half-life of roughly 20–30 hours versus around 10 minutes for unmodified IGF-1, allowing once-daily subcutaneous dosing to produce sustained receptor activation. Mechanistically, IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) and downstream effectors of the PI3K/Akt pathway, driving protein synthesis, nutrient partitioning and — distinct from most anabolic compounds — hyperplasia, the formation of new muscle fibres rather than enlargement of existing ones. It does not bind the androgen receptor and does not suppress endogenous testosterone.

IGF-1 LR3 Pharmaqo benefits

• Systemic anabolic signalling via the IGF-1R — full-body, not site-specific
• Hyperplasia: stimulates the formation of new muscle cells, not just enlargement of existing ones
• Improved nutrient partitioning, with calories preferentially routed toward lean tissue
• Faster recovery between sessions and accelerated soft-tissue repair
• Once-daily subcutaneous dosing — extended ~20–30 hour half-life vs ~10 min for native IGF-1
• No androgen receptor activity, no aromatisation, no HPTA suppression and no PCT requirement

Most users run IGF-1 LR3 alongside an existing AAS or HGH protocol to harness its hyperplastic mechanism, which is genuinely additive rather than overlapping with the hypertrophy driven by androgens.

IGF-1 LR3 dosage and cycle

Beginners: 20 mcg/day subcutaneous to assess tolerance and hypoglycaemic response. Standard: 30–40 mcg/day subcutaneous, once daily, ideally post-workout or with a carbohydrate-containing meal. Advanced: up to 50 mcg/day subcutaneous. Cycle length is typically 4–6 weeks; longer continuous use is generally avoided because IGF-1R desensitisation can blunt response over time. Reconstitute the lyophilised vial with bacteriostatic water, refrigerate after mixing and use within roughly 28 days. Subcutaneous injection into the abdomen rotates well between sites. Female-use note: IGF-1 LR3 is not androgenic and is well-tolerated by women at the lower end of the dose range (20–30 mcg/day).

Side effects and PCT

The principal acute risk is hypoglycaemia — IGF-1 LR3 has insulin-like effects on glucose uptake, and a sudden drop in blood sugar can present as light-headedness, sweating, tremor and confusion within an hour of dosing. Always have fast-acting carbohydrates (juice, glucose tablets) within reach for the first several injections. Other documented effects include site-specific tissue growth at the injection point in some users, mild fatigue or hunger spikes, and theoretical concerns over long-term IGF-1 elevation and tissue proliferation, which is why cycle length is kept short. There is no aromatisation, no liver toxicity and no testosterone suppression — and therefore no PCT required. Anyone with a personal or family history of cancer, diabetic retinopathy or active malignancy should not use IGF-1 analogues.

Stacks well with

IGF-1 LR3 pairs naturally with Qomatropin HGH 100IU for users wanting both endogenous IGF-1 elevation from somatropin and the direct, sustained IGF-1R activation that LR3 provides. For site-specific pre-workout intramuscular targeting of a lagging body part, IGF-1 DES 1-3 is the short-acting complement. Oral users who want to push IGF-1 further without additional injections often add MK-677 at bedtime to elevate overnight GH pulses alongside the LR3 daytime signal.

Frequently asked questions

How long does IGF-1 LR3 take to start working?

Receptor-level activation is immediate, but visible body-composition changes accumulate gradually. Most users report improved recovery and a fuller, more pumped feel within the first one to two weeks. Hyperplastic effects on lean tissue build over the full 4–6 week cycle and are best assessed alongside an existing AAS or HGH protocol rather than in isolation.

Is IGF-1 LR3 suitable for first-time users?

It is not a typical entry-level compound. IGF-1 LR3 carries a real hypoglycaemia risk, requires correct subcutaneous injection technique and demands proper reconstitution and refrigerated storage. Beginners are usually better served starting with a standard testosterone base or an oral compound first, and adding LR3 once injection technique and metabolic response are well understood.

Can IGF-1 LR3 be detected on a drug test?

Standard employment and amateur sports drug screens do not test for IGF-1 analogues. WADA does prohibit IGF-1 and its analogues for elite competitive athletes and uses specialist mass-spectrometry assays, but the detection window is narrow because exogenous IGF-1 LR3 clears within days. Anyone subject to WADA-grade testing should consult their governing body.